Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04718389 · ClinicalTrials.gov registry record · Phase 3
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,717
- Enrollment target
NCT04718389 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,717 participants.
The verdict
NCT04718389, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,717 participants
- Enrollment target
Study Summary
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Benralizumab
- BIOLOGICAL Mepolizumab
- DRUG Standard of care (SoC)
- BIOLOGICAL GSK3511294 (Depemokimab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,717 participants |
| Start Date | 2021-01-26 |
| Est. Completion | 2025-09-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04718389
The ClinicalTrials.gov registry entry for NCT04718389 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,717 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04718389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04718389 about?
NCT04718389 is a clinical study titled "A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype". This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophil...
What is the current status of trial NCT04718389?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,717 participants. The study started on 2021-01-26. Estimated completion is 2025-09-14.
What interventions are being tested in trial NCT04718389?
The interventions under investigation include: Placebo (BIOLOGICAL), Benralizumab (BIOLOGICAL), Mepolizumab (BIOLOGICAL), Standard of care (SoC) (DRUG), GSK3511294 (Depemokimab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04718389?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.